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Background: In 2002, the Transverse Myelitis Consortium Working Group (TMCWG) proposed the diagnostic criteria
for idiopathic acute transverse myelitis (IATM) to delimit and unify this group of patients. This study aimed to
describe the conversion rate to multiple sclerosis (MS) and variables associated with conversion, and to analyze
functional outcome and prognostic factors associated with functional recovery in patients who fulfilled the current
TMCWG criteria for definite and possible IATM.
Methods: Eighty-seven patients diagnosed with IATM between 1989 and 2011 were retrospectively reviewed. Two
patients with positive neuromyelitis optica IgG serum antibodies were excluded. Epidemiological, clinical, laboratory,
magnetic resonance imaging (MRI) data and outcome of 85 patients were analyzed.
Results: Eleven (13%) patients converted to MS after a median follow-up of 2.9 years (interquartile range 1.0-4.8).
Early-age onset of symptoms was related to conversion to MS. Only 9.4% of patients with IATM were unable to
walk unassisted at the end of follow-up. Urinary sphincter dysfunction (odds ratio [OR] 3.37, 95% confidence interval
[CI] 1.04-10.92) and longitudinally extensive transverse myelitis (LETM) on MRI (OR 12.34, 95% CI 3.38-45.00) were
associated with a poorer outcome (Rankin ≥ 2).
Conclusions: At least 13% of patients who fulfill the TMCWG criteria for definite and possible IATM will convert to MS.
Functional recovery in IATM is poorer in patients with urinary sphincter dysfunction at admission or LETM on MRI.
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In 2002, the Transverse Myelitis Consortium Working
Group (TMCWG) presented the proposed diagnos-
tic criteria for idiopathic acute transverse myelitis
(IATM) to delimit and unify this group of patients
[1]. Since that time, identification of new diagnostic
biomarkers, such as neuromyelitis optica (NMO) IgG
antibodies has contributed to differentiate new condi-
tions from the idiopathic group of acute transverse
myelitis [2].
Another distinctive group of patients with an IATM
event meeting the TMCWG criteria are individuals who
present with a first attack of multiple sclerosis (MS) in
the setting of an initially normal brain magnetic* Correspondence: acobo@bellvitgehospital.cat
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distribution, and reproduction in any mediumresonance imaging (MRI) study. The percentage of pa-
tients with TMCWG criteria for IATM who have a first
demyelinating MS event remains to be clarified.
Individuals considered at a high risk of disability after
a first IATM event may benefit from treatments that are
more aggressive, such as plasma exchange. Hence, there
is a need to identify this cohort of patients early in the
course of the disease.
The aim of this study was 1) to describe the conver-
sion rate to MS and identify variables associated with
conversion, and 2) to analyze the functional outcome
and prognostic factors associated with recovery in
patients who fulfill the current TMCWG criteria for
possible and definite IATM.ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Patients
The study was approved by the Clinical Research Ethics
Committee of Bellvitge University Hospital and all data
were collected in an anonymized fashion (ref PR228/12).
We reviewed 604 medical records from patients with
neurological signs attributed to spinal cord inflammation
assessed at Bellvitge University Hospital (Barcelona,
Spain) between January 1989 and December 2011.
Among them, we found 487 patients diagnosed with MS
who presented a spinal cord inflammation or a first
spinal cord inflammation with cranial MRI suggestive of
MS, 11 due to parainfeccious disease, systemic disease in
9, spinal cord infarction in 3 patients and ADEM, dural
fistula and tumoral-related spinal cord in 2 patients re-
spectively. One patient had simultaneous myelitis and
optic neuritis (ON) as a part of the classic Devic Syn-
drome. We found out 87 patients initially diagnosed
with IATM and no history of previous neurological
symptoms.
We then retrospectively studied these 87 patients. Pa-
tients who fulfilled the criteria for IATM proposed by
the TMCWG (definite IATM) and those who met all cri-
teria with the exception of ‘objective documentation of
inflammation within the spinal cord’ (possible IATM)
were included and analyzed in the present study. The
current cohort includes the patients who were described
in a previously published study [3].
In 38 of the 87 patients, serum samples were tested
for NMO-IgG antibodies by immunohistochemistry, as
described elsewhere [4]. NMO-IgG antibodies could not
be systematically sought, as the technique became avail-
able in our hospital in 2007. This validated technique
has shown a sensitivity (S) of 50-60% and a specificity
(Sp) of more than 90%. Two patients showed positive re-
activity and were excluded from the study. Both patients
developed NMO disease, based on the diagnostic criteria
for this condition [5].
The 85 patients fulfilling the criteria for definite and
possible IATM were classified into two groups: the IATM
group and the MS group. The diagnosis of MS was based
on the revised Poser or McDonald criteria [6,7].
Epidemiological and clinical data
Sex, age at symptoms onset, season of onset and time to
reach maximum functional deficit were recorded. Hyper-
tension, hypercholesterolemia, diabetes mellitus, smok-
ing habit, traumatic events, and symptoms related to
infection (eg, flu, gastrointestinal, or urinary tract symp-
toms) within one month before the onset of IATM
symptoms were also collected. Clinical findings were
noted, such as urinary sphincter dysfunction or anal
sphincter dysfunction, and the treatment received. None
of the patients were receiving immunosuppressants orcorticosteroids before the acute spinal event or at the
time immunological studies were performed.
Disability was evaluated on admission and at last visit
using the modified Rankin Scale [8]. Rankin scores were
categorized into <2 and ≥2 to distinguish functional dis-
ability. Patients who converted to MS were further eval-
uated by the Expanded Disability Status Scale (EDSS) to
determine the extent of the neurological disability at the
last visit.
Laboratory data
A spinal tap was performed in all patients before treat-
ment. CSF was analyzed for glucose concentration, cell
count, and IgG index (positive, >0.7), and immunofixation
electrophoresis was used for oligoclonal band (OCB)
testing.
Imaging data
In all patients, baseline and follow-up MRI scans were
performed on a 1.5-Tesla system. MRI study included
axial and sagittal images of the brain and spinal cord
obtained by T1, T2, FLAIR and T1 post-contrast se-
quences. All patients had normal brain MRI findings at
the first episode of IATM. All underwent spinal MRI on
admission, and the number, location, and length of le-
sions were noted. Longitudinally extensive transverse
myelitis (LETM) was defined as extension over three or
more vertebral segments on MRI study.
Follow-up
Patients were followed-up with a neurological evaluation
every 6 months during the first year, and once a year
thereafter. Follow-up time was established as the differ-
ence between the date of the last visit and the date of
admission. Analysis of data was performed on December
2012. An additional neurological examination was
performed when a relapse occurred. Relapse was defined
as a second demyelinating event at the spinal cord
(recurrence) or other central nervous system structure
at least one month after the first event, sustained for a
minimum of 24 hours. The date of MS conversion was
noted in all patients in the MS group.
Statistical analysis
Categorical variables and ordinal variables were com-
pared with the chi-square test and Mann–Whitney U
test, respectively. Correlations between ordinal variables
were analyzed with Pearson’s correlation coefficient.
Quantitative continuous variables were compared with
the Student t test. Multivariate logistic regression ana-
lysis was performed using the forward stepwise method
and including only those variables that were statistically
different in the univariate analysis at a significance level
of p-value < 0.05. After the Bonferroni correction the
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Results
Epidemiological and clinical data
Among the 85 IATM patients included in the study,
45 (53%) were women and mean age at onset was 43 ±
16.2 years. Seventy-four patients were ultimately classi-
fied in the IATM group (87%) and 11 (13%) in the MS
group. Epidemiological and clinical data are shown in
Table 1 and Table 2.
In the MS group, patients with a relapse after the first
spinal cord event presented with typical symptoms of
MS; three had ON, one sensory and sphincter dysfunc-
tion, one sensory and motor symptoms, two pure motor
symptoms and three pure sensory symptoms. Nine pa-
tients had relapsing-remitting MS and two progressed to
secondary progressive MS (SPMS). One SPMS patient
experienced no further relapses after the first spinal
attack.
At the end of follow-up, myelitis recurred in 5 pa-
tients, all in the MS group. No patients with LETM had
recurrences. Two patients with a first LETM who
converted to MS did so at one and seven months from
the first attack, respectively.
Patients with onset of symptoms in summer reached
nadir faster than the remaining patients (7.94 days,
SD 7.5 vs 3.14 days, SD 3.08, p < 0.001).Table 1 Epidemiological and clinical characteristics of patient
follow up
Outcom
<2
N (%) 51 (60)
Age, mean (SD), y 38.9 (14)
Sex, male/female 21/30
Follow up, median (IQR), y 2.9 (1.5-4.1)
Time to maximum deficit, mean (SD), d 7.2 (7)
Admission Rankin Mean (SD) 2.27 (1)
Outcome Rankin Mean (SD) ____
Time onset-start treatment, mean (SD), d 9.7 (8.3)
Back pain, n (%) 19 (37.3)
Urinary sphincter dysfunction, n (%) 21 (41.2)
Anal sphincter dysfunction, n (%) 2 (4)
Previous infection, n (%) 19 (37.3)
Summer season/Not summer season, n (%) 9/49 (18) /40/49 (81.6)
TM relapses, n (%) 5/51 (9.8)
MS conversion, n (%) 8 (15.7)
IQR: Interquartile range.
SD: Standard deviation.
TM: Transverse myelitis.
aSignificant after Bonferroni correction.Treatment with intravenous methylprednisolone (1 g
daily for 5 days) was given to 67 patients. Three patients
(two of whom presented as LETM) needed further treat-
ment, such as plasma exchange, due to a poor response
to corticosteroids and symptoms of impairment at ad-
mission (Rankin Score was 3, 5 and 4, respectively).
Among the MS group, seven patients were treated
with disease modifying drugs during the follow up.
CSF findings
CSF cell count was determined in 77 patients and pleo-
cytosis (total cellularity >5 cell/mm3) was found in 18
(23.4%). Among the 10 MS group patients in whom cell
count was performed, 5 had less than 5 cell/mm3 and
only 1 had more than 50 cell/mm3.
Five out of 15 patients with OCB in CSF developed
MS compared with only one out of 44 without OCB.
The presence of OCB was associated with conversion to
MS, but the results were not statistically significant after
Bonferroni adjustment (p = 0.003) (S 83.3%, Sp 81.5%,
positive predictive value [PPV] 33.3%, negative predictive
value [NPV] 97.8%). The IgG index was not, however,
related to MS conversion (p = 0.800) (S 60%, Sp 80%,
PPV 23.1%, NPV 95%). The combination of positive
OCB testing and IgG index >0.7 yielded a negative pre-
dictive value and sensitivity of 100% to MS conversion.
(S 100%, Sp 68.6%, PPV 23.8%, NPV 100%) (p = 0.011).
CSF data are shown in Table 3 and Table 4.s with low versus high Rankin Scores at the final of the
e Rankin p Total
≥2
34 (40) 85
49 (17.7) 0.005 43 (16.2)
19/15 0.194 40/45
2.7 (0.3-7.4) 0.683 2.9 (1–4.8)
6.91 (7.6) 0.821 7.1 (7.1)
3.65 (1.1) <0.001a 2.82 (1.2)
____ ____ 1.4 (1.3)
8.5 (8) 0.602 9.2 (8.1)
16 (47.1) 0.380 35 (41.2)
26 (76.5) 0.001a 47 (55.3)
9 (26.5) 0.002 11 (13)
8 (23.5) 0.237 27 (31.8)
5/34 (14.7) / 29/34 (85.3) 0.661 14 (16.47) /69 (81.17)
0/33 (0) 0.085 5/84 (6)
3 (8.8) 0.513 11 (13)
Table 2 Epidemiological and clinical characteristics comparing IATM versus MS group
IATM MS p
group group
N (%) 74 (87) 11 (13)
Age, mean (SD), y 45 (16) 28.2 (9.1) 0.001a
Sex, male/female 36/38 4/7 0.529
Follow up, median (IQR), y 2.9 (0.9–3.9) 9.9 (2.7–17.8) <0.001a
Time to maximum deficit, mean (SD), d 6.9 (7.2) 8.5 (7) 0.487
Admission Rankin, Mean (SD) 2.8 (1.2) 2.45 (1.1) 0.284
Outcome Rankin Mean (SD) 1.3 (1.3) 1.8 (1.2) 0.290
Time onset-start treatment, mean (SD), d 9 (8.1) 2 (2.2) 0.553
Back pain, n (%) 30 (40.5) 5 (45.5) 0.755
Urinary sphincter dysfunction, n (%) 41 (55.4) 6 (54.5) 0.603
Anal sphincter dysfunction, n (%) 10 (13.5) 1 (9.1) 0.566
Previous infection, n (%) 23 (31.1) 4 (36.4) 0.485
Summer season/Not summer season, n (%) 13/72(18.1)/59/72 (81.9) 1/11 (9.1)/10/11 (90.9) 0.460
TM relapses, n (%) 0/73 (0) 5/11 (45.5) <0.001a
IATM: Idiopathic acute transverse myelitis.
MS: Multiple Sclerosis.
IQR: Interquartile range.
SD: Standard deviation.
TM: Transverse myelitis.
aSignificant after Bonferroni correction.
Table 3 CSF and MRI characteristics with low versus high
Rankin Scores at the final of the follow up
Outcome Rankin p Total
<2 ≥2
N (%) 51 (60) 34 (40) 85 (100)
CSF (mean, SD)
Glucose, mmol/L 3.5 (1.1) 4 (1) 0.035 3.7 (n:78)
Cell count, n/mm3 8.9 (24.1) 27.8 (125.4) 0.321 16.5 (n:77)
Protein, g/L 0.4 (0.2) 0.5 (0.2) 0.389 0.5 (n:78)
OCB+, n (%) 12/40 (30) 3/20 (15) 0.343 15/60 (25)
IgG index >0.7, n (%) 8/33 (24.2) 5 /22 (22.7) 0.581 13/ 55 (23.6)
MRI
Vertebral segments,
n, mean (SD)
1.7 (1.9) 3.8 (3.3) 0.003 2.5 (2.8)
LETM (%) (9.8) 21 (61.8) <0.001a 26 (30.6)
GD+, n (%) 14/30 (46.6) 8/21 (38.1) 0.800 22/51 (43.1)
Time onset-MRI,
Mean (SD), d
9.84 (7.2) 8.37 (7.5) 0.408 9.26 (7.3)
CSF: Cerebrospinal fluid.
OCB+: Positive oligoclonal band test.
MRI: Magnetic resonance imaging.
LETM: Longitudinally extensive transverse myelitis.
GD+: Gadolinium enhancement.
SD: standard deviation.
aSignificant after Bonferroni correction.
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Spinal cord MRI revealed a cervical lesion in 31 (36.5%),
thoracic lesion in 33 (38.8%), and lumbar lesion in 11
(12.9%) of 85 patients. In 19 (22.5%) patients, no abnor-
malities were observed in the first spinal cord MRI. Five
of these 19 patients showed abnormal CSF findings
(positive IgG index and/or pleocytosis) and one patient
had a cervical lesion in the second spinal cord MRI. The
remainder showed no abnormal findings in the second
MRI. All the patients with a normal first spinal cord
MRI had abnormal neurological signs suggestive of
transverse myelitis, as the TMCWG points out. There
were no statistically significant differences between the
IATM and MS groups with regard to the location of the
MRI signal abnormality. None of the patients in the MS
group developed lumbar myelitis.
Within the MS group, six patients fulfilled the
Barkhof criteria in a subsequent brain MRI. The dis-
tributions of the lesions in the axial plane at the first
spinal MRI were predominantly posterior (4/11) and
lateral (2/11), and two patients had a lesion area that
extended over more than 50% of the spinal cord sec-
tion. In three MS patients, the first spinal MRI was
normal and the subsequent spinal study revealed a
single cervical lesion in one of them. Nine MS pa-
tients underwent a second spinal MRI; in three the
lesion had resolved, three had new spinal lesions that
extended over fewer than three vertebral segments,
and three showed no changes.
Table 4 CSF and MRI characteristics comparing IATM
versus MS group
IATM MS p
group group
N (%) 74 (87) 11 (13)
CSF (mean, SD)
Glucose, mmol/L 3.7 (1.1) 3.4 (0.6 0.424
Cell count, n/mm3 17.4 (87.1) 10 (18.4) 0.789
Protein, g/L 0.5 (0.2) 0.35 (0.2) 0.044
OCB+, n (%) 10/54(18.5) 5/6 (83.3) 0.003
IgG index >0.7, n (%) 10/50 (20) 3/5 (60) 0.800
MRI
Vertebral segments,
n, mean (SD)
2.6 (2.8) 2 (2.2) 0.403
LETM (%) 24 (32.4) 2 (18.2) 0.281
GD+, n (%) 20/43 (46.5) 2/8 (25) 0.309
Time onset-MRI,
Mean (SD), d
8.56 (7) 14.22 (8.1) 0.029
IATM: Idiopathic acute transverse myelitis.
MS: Multiple Sclerosis.
MRI: Magnetic resonance imaging.
CSF: Cerebrospinal fluid.
OCB+: Positive oligoclonal band test.
LETM: Longitudinally extensive transverse myelitis.
GD+: Gadolinium enhancement.
SD: Standard deviation.
aSignificant after Bonferroni correction.
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lated to greater disability. In this group, 81% of patients
had a Rankin score ≥2 at their last visit compared with
22% of patients without LETM (p < 0.001). The fact of
having LETM did not rule out conversion to MS: two of
26 patients (7.5%) with LETM developed MS.
Twenty-two of 26 patients with LETM presenting as
IATM were seronegative for NMO-IgG antibodies at
presentation and during follow-up. In the four remaining
LETM patients, NMO-IgG antibodies were not analyzed:
two patients converted to MS and two died from
myelopathy-unrelated etiology after two and three years
of follow-up, respectively. Additional MRI data are
shown in Table 3 and Table 4.
Follow-up and outcome
Among the whole cohort, the median follow-up time
was 2.9 years (IQR 1.0-4.8). The median follow- up was
quite long in the MS group, which had a median follow-
up time of 9.9 years (IQR 2.7-17.8) compared to the
IATM group with a median of 2.9 years (IQR 0.9-3.9).
The patients converted to MS at a median of 1.2 years
(IQR 0.37-1.87) after the first spinal cord event. At com-
pletion of follow-up, early age at onset of symptoms was
related to conversion to MS in patients who fulfilled
criteria for possible or definite IATM (Table 2). Data
related to follow-up and outcome are shown in Figure 1.Modified Rankin Score results at admission and end
follow-up are shown in Table 5. A higher admission
Rankin score was significantly related to a poorer out-
come (Pearson correlation coefficient 0.65; p < 0.001).
Thirty-three patients (97.1%) with functional disability at
the last visit had an admission Rankin ≥2 (p = 0.006).
Among 71 patients with a score ≥2 at admission, 33
(46.5%) had an outcome Rankin ≥2 (p = 0.006).
Urinary sphincter dysfunction was the only clinical
symptom related to Rankin ≥2 at last visit (p < 0.001)
(Table 1).
Independent risk factors associated with an outcome
Rankin score ≥2 were urinary sphincter dysfunction (OR
3.37, 95% CI 1.04-10.92) and LETM (OR 12.34, 95% CI
3.38-45.00).
Discussion and conclusions
To the best of our knowledge, the 85 patients in the
present study represent the largest series meeting the
criteria for possible and definite IATM established by
the TMCWG.
NMO spectrum disorders (NMOSD) are considered
limited forms of NMO, such as single or recurrent
LETM events or relapsing or simultaneous bilateral ON
with positive serum NMO-IgG testing [9]. At onset of
symptoms, NMO may not be easily distinguishable from
IATM presenting as LETM, and NMO-IgG has been
suggested as the most reliable marker to identify patients
with this condition [2]. However, a recent report has in-
dicated that positive NMO-IgG status may not be
needed to reach a definite diagnosis in 90% of patients
with clinically suspected NMO [10]. Among the idio-
pathic LETM patients presented here, all were seronega-
tive, although in four patients, NMO-IgG were not
analyzed. Two of these patients converted to MS and
the other two died without presenting further relapses of
either myelitis or ON. After excluding NMOSD and MS,
recurrence of IATM or even LETM is rare in our experi-
ence. Monophasic isolated LETM might represent a dis-
tinct clinical syndrome, as others have suggested [11,12].
Studies analyzing CSF in IATM have reported pleocy-
tosis in a high percentage of patients (42%-62%) [13-15].
Because patients with spinal cord ischemia show no CSF
pleocytosis, it has been proposed that CSF leukocyte
count could be a useful marker to differentiate inflam-
matory myelopathies from spinal cord infarcts [16]. In
our series, however, a lower percentage of patients had
pleocytosis (23.4%) than the reported rates. Because nor-
mal CSF cell counts can be found in both conditions,
this marker would likely be of limited usefulness to iden-
tify IATM.
According to our findings, IATM presenting as LETM
does not rule out a first demyelinating MS. These results
are in agreement with a prospective study investigating
Figure 1 Diagram reflecting the prognosis of outcome in the different subgroups. IATM idiopathic acute transverse myelitis, TMCWG
Transverse Myelitis Consortium Working Group, LETM longitudinally extensive transverse myelitis, NMO-IgG neuromyelitis optica IgG antibodies,
MTP methylprednisolone, PLEX, plasma exchange, EDSS Expanded disability Status Scale, mRS modified Rankin Scale, IQR interquartile range.
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with a poorer prognosis in patients with acute transverse
myelitis [18,19] and recently, longer extension of LETM
has been related to a higher number of relapses [17]. In
our series, LETM was the most important independent
risk factor for long-term disability.
Up to 50% of patients with neurological symptoms
suggestive of spinal cord inflammation had normal
spinal cord MRI [20]. In our study, 15.2% of patients
neither showed evidence of lesions at first or subsequent
spinal MRI nor revealed paraclinical data supporting
inflammation within spinal cord. TMCWG criteria
includes such a patients as ‘possible ATM’.
Early studies reported that up to one third of patients
with a first episode of acute transverse myelitis remainedTable 5 Disability at admission and last follow-up visit
mRS Admission Last visit
n (%) n (%)
0 0 27 (31.8)
1 14 (16.5) 26 (30.6)
2 22 (25.9) 11 (12.9)
3 21 (24.7) 13 (15.3)
4 21 (24.7) 7 (8.2)
5 7 (8.2) 1 (1.2)
6 0 0
mRS modified Rankin Scale.unable to walk [21,22]. Most studies carried out after es-
tablishment of the TMCWG criteria disclosed similar
rates of poor outcome ranging from 11% to 35.8%
[13,18,23]. In our series, only 9.4% of patients were un-
able to walk unassisted at completion of follow-up
(Rankin ≥4). Differences in the length of follow-up,
together with methodological aspects (collaborative mul-
ticenter studies vs hospital-based series), may have con-
tributed to the better outcome in our cohort, compared
to others [14,17].
Several clinical factors associated with a poor outcome
have been described in patients with acute transverse
myelitis, including back pain, severe functional deficit
and motor involvement at onset of symptoms, symptoms
progression within 24 hours, relapse occurrence, and
spinal shock [3,14,21,22,24]. As was mentioned above,
among the para-clinical factors, LETM has been associ-
ated with a poor prognosis in these patients [18,19]. The
multivariate analysis in the present study showed that
urinary sphincter dysfunction and LETM were inde-
pendently associated with a poor prognosis in IATM.
Regarding patients with a first event involving an iso-
lated spinal cord lesion, it is well recognized that partial
myelitis is highly predictable of progression to MS
[15,25]. Previous studies in IATM have reported a con-
version rate of 0% [14,18] to 11.4% [23], with a mean
follow-up ranging from 2 to 4.8 years. Therefore, in ac-
cordance with the results of our study, conversion to
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IATM patients. MS patients had a longer median follow-
up compared with IATM patients. Although this differ-
ence might result in a lower conversion rate in the
IATM group, MS patients showed a median time to con-
version of 1.2 years (IQR 0.37-1.87) and the median
follow-up time in the IATM group was 2.9 years. There-
fore, IATM patients will unlikely convert to MS.
IATM patients testing positive for OCB in CSF had an
increased risk of developing MS in the follow-up (33.3%
vs 2% conversion rate). In contrast, the combination of
negative OCB testing and IgG index ≤0.7 yielded a very
low likelihood of converting to MS (NPV 100%). These
data are in keeping with the results of previous studies
investigating the utility of CSF findings in patients with
a clinically isolated syndrome who convert to MS [26].
Age, family background, sensory symptoms, greater
disability at onset of symptoms, brain MRI lesions, pres-
ence of OCB, and an abnormal CSF IgG index are
reported predictive factors of conversion to MS in pa-
tients with a clinically isolated cord syndrome [27-29].
We found that in patients with an initial IATM, onset of
symptoms at an early age is related to conversion to MS.
In addition, patients with a normal IgG index and no
evidence of OCB in CSF have a very low risk of
converting to MS.
In addition to the retrospective nature of the case
series, our study has other limitations. Firstly, our study
was not designed to evaluate treatment response and
therefore we could not consider therapeutic aspects
when analyzing long term outcome. Secondly, a single
centre design may be considered as a limitation although
our hospital is a reference centre for patients with clin-
ical symptoms suggestive of acute myelopathy in our
sanitary district. Finally, we consider that the patients
included herein will unlikely develop NMO: the sero-
negative status in LETM patients, the absence of other
neurological signs such as ON, the relatively good final
outcome and the absence of recurrence after almost
3 years of follow-up support the diagnosis of IATM
[30,31].
In conclusion, our results indicate that at least 13% of
patients who fulfill the TMCWG criteria for definite and
possible IATM will convert to MS. Functional recovery
in IATM is poorer in patients with urinary sphincter
dysfunction at admission and findings of LETM on MRI
study.
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